Many Arrowhead Pharmaceuticals, Inc.(ARWR) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Arrowhead Research Corp was Downgraded by Piper Jaffray to Neutral on Nov 30, 2016. Arrowhead Research Corp was Downgraded by Chardan Capital Markets on Nov 30, 2016 to Neutral, Lowers Price Target to $ 2 from a previous price target of $8 .Arrowhead Research Corp was Downgraded by William Blair to Mkt Perform on Nov 30, 2016. Arrowhead Research Corp was Downgraded by Cantor Fitzgerald to Hold on Nov 30, 2016.
Company has reported several Insider transactions to the SEC, on Oct 18, 2016, Douglas B Given (director) sold 12,000 shares at 6.72 per share price.On Aug 24, 2016, Kenneth Allen Myszkowski (Chief Financial Officer) sold 20,000 shares at 8.00 per share price.On Jan 14, 2015, Mauro Ferrari (director) purchased 2,300 shares at 6.90 per share price.
Arrowhead Research Corp Last issued its quarterly earnings results on Aug 9, 2016. The company reported $-0.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.04. Analyst had a consensus of $-0.36. The company had revenue of $39.58 million for the quarter, compared to analysts expectations of $.05 million. The companys revenue was down -68.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.27 EPS.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): The mean short term price target for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been established at $2.67 per share. The higher price target estimate is at $7 and the lower price target estimate is expected at $1 according to 6 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $2.16
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rose 4.15% or 0.08 points on Tuesday and made its way into the gainers of the day. After trading began at $1.94 the stock was seen hitting $2.03 as a peak level and $1.9 as the lowest level. The stock ended up at $2.01. The daily volume was measured at 687,575 shares. The 52-week high of the share price is $8.22 and the 52-week low is $1.2. The company has a market cap of $150 million.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The companys proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.